{"filings":[{"id":946838,"accession_number":"0001171843-26-004008","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-06-09T20:42:02+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axe Compute files updated risk factors reflecting shift to owned GPU data center model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company expands to own GPU hardware in data centers, shifting from asset-light model; expects significant capital expenditures for procurement and deployment.","Dependence on NVIDIA for GPU supply; any disruption could delay Q3 2026 deployment and materially affect business.","Largest contract concentrated in single facility requiring 4.8 MW power; power outages or cost increases could impact operations.","Revenue expected to be concentrated among few customers; loss or non-performance could disproportionately harm results.","Rapid GPU technological obsolescence poses risk of accelerated depreciation or impairment charges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":481485,"accession_number":"0001171843-26-003492","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-05-15T22:13:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axe Compute signs $260M contract, Q1 net loss $7.7M, first compute revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["$260M 36-month take-or-pay contract for 2,304 NVIDIA B300 GPUs; deployment Q3 2026, expected $21M/quarter revenue.","Q1 2026 net loss $7.7M ($0.36 EPS) on $35K revenue; includes $4.3M non-cash mark-to-market loss on digital assets.","First compute services revenue recognized; contract liabilities $645K from customer prepayments.","Appointed Kyle Okamoto President and Jeremy Yaukey-Witter CFO; evaluating sale of Drug Discovery business.","Liquidity $36.5M: $6.9M cash, $20.2M in ATH digital assets, $9.4M current digital asset receivable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":35311.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":473276,"accession_number":"0001171843-26-003489","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-05-15T21:30:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axe Compute ups ATM offering capacity to $100M, removes prior cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement raising maximum ATM shares to $100,000,000 aggregate value.","Company sold ~$12.7M in stock during prior 12 months through H.C. Wainwright.","No longer subject to General Instruction I.B.6 of Form S-3 offering limitations.","ATM agreement with H.C. Wainwright & Co., LLC remains in effect.","Proceeds intended for general corporate purposes (not explicitly stated but typical)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":42401,"accession_number":"0001171843-26-003313","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-05-12T21:01:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Axe Compute announces Q1 2026 earnings conference call for May 18","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Conference call to review Q1 2026 results on May 18, 2026, at 8:30 a.m. ET.","Dial-in: +1 719 359 4580, Meeting ID: 85815757358, Passcode: 045753.","Webcast available via Sequire; replay on investor relations website.","No financial results disclosed in this filing; only call details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92912,"accession_number":"0001171843-26-002636","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axe Compute secures $260M, 3-year contract for 2,304 NVIDIA B300 GPUs; largest enterprise deal ever","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate contract value of ~$260M over 36 months for dedicated GPU compute and high-speed storage.","Deployment of 2,304 NVIDIA B300 GPUs in a single U.S. Tier 3 data center; targeted start Q3 2026.","Payment structure includes deposit, prepayment, and monthly take-or-pay payments; renewal options.","Dedicated 4.8 MW power with N+1 redundancy; cluster purpose-built for AI training, fine-tuning, inference.","Contract represents the largest enterprise engagement in Axe Compute's history."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92911,"accession_number":"0001171843-26-002517","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Axe Compute CFO Josh Blacher resigns; Jeremy Yaukey-Witter appointed as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Josh Blacher resigns effective May 18, 2026; departure not due to any disagreement with the company.","Jeremy Yaukey-Witter appointed co-CFO Apr 16–May 18, then sole CFO; previously Controller since Apr 2023.","Yaukey-Witter receives annual base salary of $280,000, bonus target 0–40% of salary, and 225,000 stock options at $3.51/share.","Options vest over three years (1/3 at one-year anniversary, then monthly); exercise price $3.51, ten-year term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92910,"accession_number":"0001171843-26-002182","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Axe Compute reports $12M contract value, $835K/month income; names new President","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$12M executed agreement value in last 30 days; 20+ enterprise customers, 30+ active deployments across AI/enterprise verticals.","Estimated $835K monthly income upon deployment entering Q2; ~$7.5M estimated income from signed contracts in 2026 based on run rate.","Kyle Okamoto appointed President effective Apr 1, 2026; previously CTO of Aethir, senior roles at Ericsson and Verizon.","Employment: $360K base, $500K bonus target, inducement options for 300K shares at $1.62 vesting over 3 years.","Enterprise contracts structured with monthly payment in advance, eliminating receivables risk and supporting predictable income."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104139,"accession_number":"0001171843-26-002096","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axe Compute reports FY2025 net loss of $232.9M; no compute revenue; holds $40M in ATH tokens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $125,284, entirely from legacy Drug Discovery; no compute revenue in 2025.","Net loss from continuing ops $232.9M, including $152.5M unrealized loss on digital assets (ATH) and $52.7M derivative loss.","Cash and equivalents $10.8M vs $0.6M; stockholders' equity improved to $47.7M from deficit of $0.2M.","Held 6.348B ATH tokens aggregate ($40M FMV after discount); $343.5M raised via PIPE in Oct 2025.","CEO Christopher Miglino appointed Feb 2026; board reconstituted; GPU network access over 435,000 GPUs established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104138,"accession_number":"0001171843-26-001424","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Axe Compute appoints Dr. Theodore Zhu and Thorston Dirks to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Theodore Zhu appointed to board; founder/chairman of Iotelligent Technology, former CEO of Celestial Semiconductor.","Thorston Dirks appointed to board; former CEO of E-Plus Group, Telefónica Deutschland, and Deutsche Glasfaser.","Appointments effective March 9, 2026; compensation consistent with Company's director compensation plan.","No family relationships between new directors and existing officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104137,"accession_number":"0001171843-26-000690","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axe Compute terminates CEO Vennare; appoints Miglino as new CEO, grants 500K options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raymond Vennare terminated without cause as CEO, effective Feb 9, 2026; receives $575k severance and $287.5k 2025 bonus.","Christopher Miglino appointed CEO and board member, effective Feb 9, 2026.","Miglino's annual base salary is $575k; bonus up to 50% of salary; inducement stock options for 500k shares vesting over 3 years.","Press release signals strategic focus on decentralized compute and AI infrastructure under new leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104136,"accession_number":"0001171843-26-000387","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Axe Compute loses two directors and CIO in January 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Matthews resigned as director effective Jan 15, 2026.","Veena Rao resigned as director effective Jan 30, 2026.","CIO Thomas McLaughlin resigned effective Jan 19, 2026.","All resignations stated as not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120399,"accession_number":"0001171843-25-007923","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axe Compute (fka Predictive Oncology) announces name change, new AI infrastructure strategy, CEO pay hike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company renamed Axe Compute Inc., now trades on Nasdaq under AGPU as of Dec 12, 2025.","CEO Raymond Vennare's base salary raised to $575k retroactive to Nov 1, 2025; eligible for 50% target bonus and 20,000 RSUs vesting Jan 1, 2026.","Plans to expand into high-performance AI infrastructure via Aethir network GPU capacity, targeting revenue from token rewards and service margins.","Continues AI drug discovery business; no specific financial guidance or committed contracts announced.","Company cites 40-52 week GPU procurement delays and $400B global enterprise AI cloud spending as market opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120408,"accession_number":"0001171843-25-007861","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Predictive Oncology renames to Axe Compute Inc.; Nasdaq ticker becomes AGPU","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Axe Compute Inc. effective Dec 11, 2025; Certificate of Amendment filed in Delaware.","Ticker symbol changes to AGPU on Nasdaq, effective Dec 12, 2025; CUSIP unchanged.","No stockholder approval required under Delaware law; outstanding certificates remain valid.","Third Amended and Restated Bylaws adopted to reflect new name; no substantive changes.","Trading under new ticker expected to begin on or about Dec 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120407,"accession_number":"0001171843-25-007724","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Predictive Oncology regains Nasdaq minimum equity compliance; one-year monitor imposed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Dec 1, 2025 confirming compliance with minimum $2.5M stockholders' equity requirement.","Company placed under mandatory one-year panel monitor; future non-compliance could lead to delisting without cure.","CFO Josh Blacher states compliance strengthens financial position and investor confidence.","Company also disclosed digital asset treasury strategy focusing on Aethir (ATH) token."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120406,"accession_number":"0001171843-25-007595","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"POAI shareholders approve equity plan amendment adding 1M shares, warrant exercise of 14.9M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Daniel E. Handley and Chuck Nuzum elected Class I directors with over 1.7M votes each.","Amendment to 2024 Equity Incentive Plan approved, adding 1,000,000 shares available for issuance.","Issuance of 14,903,393 shares upon exercise of pre-funded warrants approved under Nasdaq Listing Rule 5635(a).","KPMG LLP ratified as independent auditor for fiscal 2025; executive compensation approved on advisory basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120405,"accession_number":"0001171843-25-007488","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Predictive Oncology raises $343.5M via PIPE, regains Nasdaq equity compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed two PIPE transactions on Oct 7, 2025, receiving ~$343.5M total ($50.8M cash + ~$292.7M notional crypto assets valued at ~$173.3M discounted).","Company believes stockholders' equity now exceeds $2.5M, regaining compliance with Nasdaq Listing Rule 5550(b)(1).","Previously reported non-compliance in Nov 2024; now cured as of Nov 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120404,"accession_number":"0001171843-25-007372","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Predictive Oncology schedules Q3 call; updates on digital asset treasury strategy with ATH","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company will hold conference call at 9:00 AM ET on Nov 17, 2025 to discuss Q3 2025 financial results.","Digital asset treasury strategy involves ATH tokens and the Aethir ecosystem.","Pre-funded warrants issued in a private placement in exchange for locked and unlocked ATH.","No specific Q3 financial figures or guidance were included in the furnished presentation excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120403,"accession_number":"0001171843-25-007344","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Predictive Oncology Q3 EPS loss $(107.24); records $74.4M derivative liability on ATH token strategy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $3,618 virtually unchanged from $3,907 in Q3 2024; cash fell to $181,667 from $611,822 at Dec 31, 2024.","GAAP net loss per share from continuing operations of $(107.24), including a $74.4M loss on derivative instruments.","Held 5.70 billion ATH tokens as of Nov 10, 2025; market value ~$152.8M, with 3.7B locked and 2.0B unlocked.","Received ~$50.8M cash proceeds and ~$292.7M in-kind ATH notional from two private placements under new digital asset treasury strategy.","Appointed Shawn Matthews (former CEO of Cantor Fitzgerald) to Board of Directors; strategic collaboration with Every Cure announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":116610.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120402,"accession_number":"0001171843-25-006772","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Predictive Oncology updates ATM offering capacity to $18.33M under Form S-3 limit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement amending ATM agreement with H.C. Wainwright; maximum aggregate offering price set at $18.33M as of Oct 29, 2025.","Sold approximately $2.42M in common stock during prior 12 months under General Instruction I.B.6 of Form S-3.","If public float exceeds $75M, I.B.6 limit no longer applies, allowing larger sales without further supplement.","Legal opinion from DLA Piper LLP on shares issuable under ATM program attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120401,"accession_number":"0001171843-25-006489","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Predictive Oncology sets 2025 annual meeting for Nov 25; proposal deadline Oct 26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for November 25, 2025 at DLA Piper offices in Pittsburgh.","Record date for determining stockholders entitled to vote is October 24, 2025.","Stockholder proposals and proxy access requests must be received by October 26, 2025.","Definitive proxy materials expected to be mailed on or about November 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120400,"accession_number":"0001171843-25-006348","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Predictive Oncology closes $343.5M private placements to launch digital asset treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$50.8M cash via 4.4M shares at $11.6265; plus ~$292.7M notional from in-kind ATH tokens.","Proceeds to fund digital asset treasury (ATH tokens) and for working capital and general purposes.","Shawn Matthews of DNA Holdings to join board; DNA acted as strategic advisor and investor in Cash PIPE.","Pre-funded warrants from Crypto PIPE require shareholder approval before exercisable.","Reverse stock split 1-for-15 effective Sept 30, 2025; all share/price info presented post-split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136986,"accession_number":"0001171843-25-006154","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Predictive Oncology launches private placements for cash and crypto, shifts to ATH token treasury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash offering: ~55.2M shares at $0.7751/share plus pre-funded warrants for 11.5M shares. Cryptocurrency offering: pre-funded warrants for ~223.6M shares with investors tendering ATH tokens.","Company adopts digital asset treasury strategy focused on ATH; proceeds from offerings to buy ATH and generate yield via staking/lending, managed by DNA Holdings.","Board changes: Nancy Chung-Welch resigns effective closing; Shawn Matthews (CEO of DNA Holdings) appointed to Board as Class II director.","Bylaw amendment caps Board size at seven directors; reverse stock split 1:15 approved by stockholders, effective Sept 30, 2025 (prices pre-split)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136985,"accession_number":"0001171843-25-006119","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Predictive Oncology raises $344M in private placements, pivots to digital asset treasury with Aethir tokens","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash PIPE: $51.7M gross from 66.7M shares at $0.7751; Crypto PIPE: $292.7M notional ($173.3M discounted) in ATH tokens.","Proceeds to fund digital asset treasury; DCI Foundation will grant additional 20% ATH tokens on open-market purchases.","Shawn Matthews (CEO of DNA Holdings, ex-Cantor Fitzgerald) to join board upon expected Oct 2 closing.","Reverse stock split 1-for-15 approved Sept 19, effective Sept 30, 2025; all share info on pre-split basis.","Company plans 'Strategic Compute Reserve' on Aethir's decentralized GPU network spanning 200+ locations across 93 countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136984,"accession_number":"0001171843-25-006069","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Predictive Oncology approves 1-for-15 reverse stock split to meet Nasdaq bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 1:15 reverse split on Sep 19, 2025; effective Sep 30, 2025.","Post-split shares ~762,414, down from 11,436,201; fractional shares rounded up.","Split intended to bring POAI into compliance with Nasdaq minimum bid price requirement.","Standby Equity Purchase Agreement to issue up to $10M in common stock also approved by shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136983,"accession_number":"0001171843-25-005890","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Predictive Oncology grants 124,959 RSUs to CEO and 97,000 RSUs to Interim CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Raymond F. Vennare receives 124,959 RSUs; Interim CFO Josh Blacher receives 97,000 RSUs.","RSUs vest fully on October 31, 2025, subject to continued service through that date.","Grants made under the 2024 Equity Incentive Plan; form of award agreement filed as Exhibit 10.1.","Each RSU represents the right to receive one share of common stock upon vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136982,"accession_number":"0001171843-25-005680","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Predictive Oncology raises ~$413K in private placement of 543,544 shares at $0.76/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 543,544 shares at $0.76 each to accredited investor; gross proceeds ~$413K.","Net proceeds for working capital and general corporate purposes.","Investor granted 100% participation right in future equity offerings through Oct 31, 2025.","Company must file registration statement for resale within 90 days of agreement.","Restrictions on further equity issuances until Oct 31, 2025, with customary exceptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136981,"accession_number":"0001171843-25-005403","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Predictive Oncology Q2 loss $0.22/share; revenue $2.7K; ChemoFx U.S./EU launch expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Loss from continuing ops ~$2.0M; diluted EPS -$0.22 vs -$0.53 YoY.","Revenue $2,682, down 96% from $67,255 due to lower 3D model sales.","Cash $506K; stockholders' deficit $1.65M vs $202K at Dec 31, 2024.","Signed $10M standby equity purchase agreement with Yorkville Advisors.","Advanced ChemoFx market expansion; developed 3D liver models for Labcorp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":112992.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136980,"accession_number":"0001171843-25-004685","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Predictive Oncology granted Nasdaq extension through Dec 8, 2025 to regain listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearing Panel extended continued listing deadline to December 8, 2025.","Company must demonstrate compliance with $2.5M stockholders' equity and $1.00 bid price requirements.","Hearing held July 17, 2025; extension granted July 23, 2025.","Previously disclosed bid price deficiency (below $1 for 30 consecutive business days) also cited.","Company pursuing actions but no assurance of regaining compliance; delisting risk remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136979,"accession_number":"0001171843-25-004558","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Predictive Oncology recasts 2024 10-K to show sold Eagan/STREAMWAY business as discontinued operations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On March 14, 2025 Predictive Oncology sold its Eagan Business (STREAMWAY fluid disposal) to DeRoyal Industries; closed March 20, 2025.","Historical financial statements for years ended Dec 31, 2024 and 2023 are revised to reflect Eagan operations as discontinued.","Filing includes revised Business, MD&A, and Financial Statements sections; not an amendment or restatement of prior 10-K.","No updates to other information or events after the original 10-K filing on March 31, 2025.","Auditor consents from KPMG and BDO USA also included as exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136978,"accession_number":"0001171843-25-004434","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Predictive Oncology of bid price deficiency; 180-day cure period to Jan 5, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 8, 2025 for failure to maintain minimum $1.00 bid price over 30 consecutive days.","Company has until January 5, 2026 to regain compliance by closing at or above $1.00 for 10 consecutive days.","If not cured by Jan 5, may be eligible for a second 180-day period if other listing standards are met.","Company intends to monitor bid price and consider options including a potential reverse stock split.","Failure to cure could result in delisting from Nasdaq Capital Market, subject to appeal rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136977,"accession_number":"0001171843-25-004367","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Predictive Oncology enters $10M standby equity purchase agreement with YA II PN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company can sell up to $10M of common stock at 96% of lowest 3-day VWAP over 36 months.","Paid $25,000 structuring fee and issued 120,482 common shares as a 1% commitment fee.","Exchange cap of 1,921,706 shares (19.99% of outstanding) unless stockholder approval or average price >= $0.83.","Investor ownership limited to 4.99% of outstanding; proceeds for working capital and general purposes.","Registration statement required before any advances; no mandatory minimum draws or non-usage fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154254,"accession_number":"0001171843-25-003836","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Predictive Oncology receives Nasdaq delisting notice for failure to meet equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Predictive Oncology June 9 of delisting for failing to meet $2.5M stockholders' equity requirement.","Company could not complete compliance plan within 180-day extension granted by Nasdaq.","Trading suspended June 18 unless appeal requested by June 16; company appealed to Nasdaq Hearings Panel.","Appeal stays suspension; Panel may grant exception up to 180 days.","No assurance of continued listing; company evaluating all options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154253,"accession_number":"0001171843-25-003768","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Predictive Oncology updates ATM offering cap to $3.4M under prospectus supplement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement limiting ATM sales to $3,398,000 aggregate under General Instruction I.B.6.","Already sold $684,467 in shares under the ATM program as of June 2, 2025.","Cap may increase if public float rises; currently subject to one-third of public float limit.","No other material events reported; filing includes legal opinion from DLA Piper."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154252,"accession_number":"0001171843-25-003205","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Predictive Oncology Q1 loss $2.3M; revenue up to $110k; cash position improves to $3.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $2.3M ($0.32 per share) vs $0.88 loss per share YoY.","Revenue $110,310 vs $4,858 YoY, driven by completion of tumor-specific 3D model.","Cash and equivalents $3.1M at March 31, 2025, up from $611k at Dec 31, 2024.","Sold Skyline Medical assets to DeRoyal; sharpens focus on AI/ML drug discovery.","Plans European launch of ChemoFx assay for ovarian/gynecological cancers; expanded US availability."],"consensus_eps_estimate":-1.377,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":110310.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154249,"accession_number":"0001171843-25-002315","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K/A","filed_at":"2025-04-18T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Predictive Oncology ends merger talks with Renovaro; no binding agreement signed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["POAI decided to discontinue discussions with RENB regarding the proposed merger.","POAI states it never entered into a merger agreement; RENB's April 4 press release claims were misrepresentations.","The letter of intent with RENB expired on March 31, 2025; POAI has no further obligations.","POAI reaffirms commitment to its AI-driven drug discovery and drug development business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154251,"accession_number":"0001171843-25-002057","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Predictive Oncology ends merger talks with Renovaro; LOI expired March 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["POAI discontinued discussions with Renovaro (RENB) regarding proposed merger; LOI expired March 31, 2025.","POAI denies entering into a binding merger agreement; contradicts RENB's April 4, 2025 press release.","Extension agreement extended LOI term to March 31, 2025; POAI has no further obligations to RENB.","POAI reaffirms commitment to AI-driven drug discovery and drug development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154250,"accession_number":"0001171843-25-001901","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Predictive Oncology FY2024 loss $10.8M on $1.6M revenue; cash drops to $0.7M; merger with Renovaro pending","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.6M essentially flat YoY; loss from continuing ops of $10.8M.","Cash and equivalents fell to $734,673 from $8.7M; stockholder deficit of ($202,610).","Net loss per share from continuing ops improved 33% to $1.99.","Raised $3M in early 2025 via asset sale, warrant exercises, and Renovaro financing.","Still working toward definitive merger agreement with Renovaro after Jan LOI."],"consensus_eps_estimate":-1.377,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":110310.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172847,"accession_number":"0001171843-25-001586","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Predictive Oncology sells Skyline Medical assets to DeRoyal for $625,000","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $625,000 plus assumption of certain liabilities including Eagan lease and accounts payable.","Assets sold include STREAMWAY product line, IP, contracts, inventory, and related equipment.","Transaction positions STREAMWAY under DeRoyal brand; aligns with merger with Renovaro Biosciences.","Skyline Medical business was non-core; company now focused on AI-driven drug discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172846,"accession_number":"0001171843-25-001284","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Predictive Oncology extends LOI with Renovaro to March 31, receives $500K initial investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["LOI amended: Renovaro's obligation to acquire certain POAI shares eliminated; termination date extended to March 31, 2025.","Renovaro paid $500,000 for 467,290 shares; additional $964,389 for 901,298 shares conditioned on definitive agreement.","Both companies expect to sign definitive merger agreement within next few weeks, per March 3 press release.","First tranche of financing received to initiate integration of AI/ML platforms and lab capabilities in US and Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172845,"accession_number":"0001171843-25-000925","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Predictive Oncology completes $545k direct offering of 363k shares at $1.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 363,336 shares at $1.50/share in registered direct offering; gross proceeds $545,004.","Offering closed on February 19, 2025; net proceeds for working capital and general corporate purposes.","H.C. Wainwright acted as exclusive placement agent; received 7% fee and 25,434 warrants at $1.875/share.","Warrants exercisable for 5 years; company agreed to 5-day lock-up and 1-year variable rate restrictions.","Shares offered under effective shelf registration statement (File No. 333-279123)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172844,"accession_number":"0001171843-25-000053","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Predictive Oncology say-on-pay fails; KPMG ratified, directors elected at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Raymond F. Vennare and Veena Rao elected with ~1.01M and ~1.00M votes for, respectively.","KPMG LLP ratified as independent auditor for 2024 (2.73M for, 358k against, 65k abstain).","2024 Equity Incentive Plan approved (682k for, 568k against, 104k abstain; ~1.8M broker non-votes).","Non-binding advisory vote on executive compensation failed (613k for, 684k against, 58k abstain; ~1.8M broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172843,"accession_number":"0001171843-25-000051","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Predictive Oncology agrees to be acquired by Renovaro for $3.00/share in preferred stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["POAI shareholders to receive 1 share of Renovaro preferred stock per POAI share, redeemable for $3.00 after 18 months.","Preferred stock convertible to Renovaro common at 1:1 after RENB trades at $4.50+ for 30 consecutive days.","Renovaro to purchase up to 2.33M POAI shares at $1.07 if warrants unexercised by Jan 15, 2025.","Merger conditioned on Renovaro raising $15M and POAI shareholder approval; definitive docs by Feb 28, 2025.","Combined company expects >30% near-term operating expense reduction via AI/ML platform synergies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189851,"accession_number":"0001171843-24-006536","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Predictive Oncology receives Nasdaq delisting notice for equity shortfall; must submit plan by Jan 6, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity $1,966,969 as of Sept 30, 2024, below Nasdaq's $2.5M minimum.","Company has 45 calendar days (until Jan 6, 2025) to submit a compliance plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","Company does not meet alternative compliance standards (market value or net income).","Listing remains effective pending plan submission; failure could lead to delisting appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189850,"accession_number":"0001171843-24-006311","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Predictive Oncology Q3 loss of $2.3M; revenue down 49%; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Loss from continuing ops of ~$2.3M on revenue of $345,686, down from $676,626 YoY.","EPS loss of $(0.36) vs $(0.68) in Q3 2023; cash fell to $3.1M from $8.7M at year end.","Board initiated process to evaluate strategic alternatives including sale or licensing to maximize shareholder value.","Implemented cost savings initiative reducing annualized cash burn by ~20%.","Raised $1.3M in July via warrant exercise of 958,117 warrants."],"consensus_eps_estimate":-4.896,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1012232.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206364,"accession_number":"0001171843-24-005297","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Predictive Oncology receives Nasdaq bid price deficiency notice; has until Mar 18, 2025 to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified on Sept 19, 2024 that POAI common stock closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until March 18, 2025, to regain compliance with minimum bid price rule.","Compliance can be regained if bid price closes at $1.00 or above for at least 10 consecutive business days.","If not cured by March 18, 2025, company may qualify for an additional 180-day compliance period.","Management will monitor bid price and consider options including a reverse stock split to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206363,"accession_number":"0001171843-24-004775","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Predictive Oncology Q2 net loss $3.2M on revenue $0.3M; enters biomarker discovery market","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.2M ($0.68 per share) on revenue of $278,722, down 43% YoY from $490K.","Cash and equivalents $5.3M at June 30, 2024; raised $3.1M net from ATM and $1.3M post-quarter from warrants.","Entering biomarker discovery market after successful ovarian cancer study with UPMC; market estimated at $51.5B.","Cost savings initiative to cut cash used in operations by ~20% annually, consolidating Birmingham lab into Pittsburgh.","Gross margin fell to 45% from 67% due to higher labor costs and lower STREAMWAY system sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":698368.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206362,"accession_number":"0001171843-24-004198","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Predictive Oncology raises $1.26M via warrant exercise at reduced price; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1.26M from immediate cash exercise of 958,117 warrants at $1.32/share (down from $14.00).","Issued new Series A (5-yr) and Series B (18-mo) warrants, each for 958,117 shares, with $1.07 exercise price.","H.C. Wainwright placement agent: 7% cash fee plus 67,068 warrants at $1.65/share.","Net proceeds combined with $3.58M from May 2024 ATM offering for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223479,"accession_number":"0001171843-24-003176","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Predictive Oncology ovarian cancer ML study results positive; to be presented at ASCO 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retrospective study with UPMC Magee-Womens Hospital used 160 multi-omic ML models to predict ovarian cancer survival.","Seven models achieved high accuracy at two-year threshold; 13 at five-year, outperforming clinical data alone.","Analysis used data from 2010-2016 including WES, WTS, drug response, and digital pathology profiles.","Top performing models identified different drivers for short- vs long-term survival, enabling future clinical decision tools.","Results presented at ASCO Annual Meeting in Chicago, June 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223478,"accession_number":"0001171843-24-002893","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Predictive Oncology Q1 net loss $4.2M on revenue $0.4M; cash $5.2M, EPS -$1.04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of ~$4.2M, wider than $3.5M loss in Q1 2023; diluted EPS -$1.04 vs -$0.86.","Revenue $419,646, up 75% YoY from $239,895, driven by STREAMWAY system sales.","Cash $5.2M at March 31, 2024, down from $8.7M at Dec 31, 2023.","Abstract accepted at ASCO 2024 for ovarian cancer machine-learning survival model; collaboration with Fujifilm on endotoxin testing announced.","FluGen collaboration for intranasal flu vaccine under $6.2M DoD grant progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":419646.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223477,"accession_number":"0001171843-24-002541","cik":1446159,"company_name":"Axe Compute Inc.","ticker":"AGPU","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Predictive Oncology enters ATM sales agreement for up to $3.7M of common stock with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM Sales Agreement with H.C. Wainwright for up to $3,696,000 of common stock.","Shares sold through 'at the market offering'; 3.0% commission to agent.","No obligation to sell; Company may set parameters including minimum price.","Registration statement on Form S-3 to be filed; sales subject to effectiveness.","Stock trades on NASDAQ Capital Market under symbol POAI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68670627.84073505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-05-06T23:59:59+00:00|223477"}